2. Anti-infection Cell Cycle/DNA Damage PI3K/Akt/mTOR Stem Cell/Wnt
  3. Bacterial Topoisomerase Akt β-catenin
  4. Ciprofloxacin

Ciprofloxacin GMP is Ciprofloxacin (HY-B0356) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Ciprofloxacin (Bay-09867) is an orally active, blood-brain barrier permeable fluoroquinolone antibacterial agent. Ciprofloxacin exerts bactericidal effects primarily by inhibiting topoisomerase II and IV. Ciprofloxacin inhibits the proliferation of human dental pulp stem cells and chondrocytes from young rats, and also activates the Akt signaling pathway and upregulates markers such as β-catenin and Nanog to maintain the morphological characteristics of stem cells. Ciprofloxacin induces significant neurotoxicity and tissue damage, including reducing serotonin and glutathione levels in the brain, inducing oxidative stress and depression-like behaviors, and causing articular cartilage damage. Ciprofloxacin can be applied to research related to infections of necrotic young permanent teeth and neurotoxicity.

For research use only. We do not sell to patients.

Ciprofloxacin

Ciprofloxacin Chemical Structure

CAS No. : 85721-33-1

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Ciprofloxacin Related Antibodies

Top Publications Citing Use of Products

View All Topoisomerase Isoform Specific Products:

View All Isoforms
Topoisomerase Topo I Topo II DNA gyrase

View All Akt Isoform Specific Products:

View All Isoforms
Akt Akt1 Akt2 Akt3

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Ciprofloxacin GMP is Ciprofloxacin (HY-B0356) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Ciprofloxacin (Bay-09867) is an orally active, blood-brain barrier permeable fluoroquinolone antibacterial agent. Ciprofloxacin exerts bactericidal effects primarily by inhibiting topoisomerase II and IV. Ciprofloxacin inhibits the proliferation of human dental pulp stem cells and chondrocytes from young rats, and also activates the Akt signaling pathway and upregulates markers such as β-catenin and Nanog to maintain the morphological characteristics of stem cells. Ciprofloxacin induces significant neurotoxicity and tissue damage, including reducing serotonin and glutathione levels in the brain, inducing oxidative stress and depression-like behaviors, and causing articular cartilage damage. Ciprofloxacin can be applied to research related to infections of necrotic young permanent teeth and neurotoxicity[1][2][3][4].

In Vitro

Ciprofloxacin (GMP) (2.5-10 μg/mL; 24-72 h) preserves the stem cell-like spindle morphology of immortalized human dermal papilla cells, and concentrations of 5 and 10 μg/mL for 72 h significantly increase cell aggregation size and number[1].
Ciprofloxacin (GMP) (10 μg/mL; 72 h) preserves CD133 stem cell marker expression and prevents increased procollagen type I fibroblast marker expression in immortalized human dermal papilla cells[1].
Ciprofloxacin (GMP) (10 μg/mL; 24-72 h) prevents time-dependent loss of CD133, integrin β1, and ALDH1A1 stem cell markers and increases in procollagen type I fibroblast marker in immortalized human dermal papilla cells; concentrations of 2.5-10 μg/mL for 72 h modulate these markers in a dose-dependent manner[1].
Ciprofloxacin (GMP) (2.5-10 μg/mL; 72 h) activates the Akt/GSK3β/β-catenin pathway in immortalized human dermal papilla cells in vitro in a dose-dependent manner, increasing activated Akt, inactivated GSK3β, and β-catenin levels[1].
Ciprofloxacin (GMP) (2.5-10 μg/mL; 72 h) activates the Akt/GSK3β/β-catenin pathway and upregulates EMT transcription factors (ZEB1, Snail) in primary human dermal papilla cells in vitro in a dose-dependent manner[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Ciprofloxacin Related Antibodies

Western Blot Analysis[1]

Cell Line: immortalized human dermal papilla cells (DPCs)
Concentration: 2.5-10 μg/mL
Incubation Time: 72 h
Result: Increased levels of phosphorylated (activated) Akt (Ser 473), phosphorylated (inactivated) GSK3β (Ser 9), and β-catenin in a dose-dependent manner, with total Akt and GSK3β levels unchanged.\nSignificantly upregulated ZEB1, Snail, N-cadherin, vimentin, phosphorylated Erk (Thr 202/Tyr 204), Nanog, and Oct-4 in a dose-dependent manner, with minimal change in Slug levels.
Parmacokinetics
Species Dose Route Cmax AUC Tmax
Rat[2] 400 mg/kg i.g. 9.6 mg/L 48.1 mg·h/L 1.5 h
Rat[2] 800 mg/kg i.g. 16.3 mg/L 97.2 mg·h/L 1.5 h
Rat[2] 1200 mg/kg i.g. 21.8 mg/L 143.1 mg·h/L 1.5 h
In Vivo

Ciprofloxacin GMP (400-1200 mg/kg; i.g.; daily; 7 days) induces dose-dependent chondrotoxicity in juvenile rats, with severe cartilage lesions, reduced cartilage thickness, and increased serum and cartilage concentrations observed at 800 and 1200 mg/kg, while no significant cartilage damage occurs at 400 mg/kg[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Sprague-Dawley (SD) (male, 4-week-old, drug-induced knee joint articular cartilage damage)[2]
Dosage: 400 mg/kg; 800 mg/kg; 1200 mg/kg
Administration: i.g.; daily; 7 days
Result: Showed no obvious cartilage alterations at 400 mg/kg.
Caused severe cartilage lesions including matrix swelling and chondrocyte loss, and significantly decreased femoral condyle cartilage thickness compared to controls at 800 mg/kg or 1200 mg/kg.
Produced a maximum serum concentration (Cmax) of 9.6 mg/L, area under the plasma concentration-time curve (AUC0-∞) of 48.1 mg·h·L-1, and cartilage concentration of 7.4 μg·g-1 at 400 mg/kg on day 1.
Produced a Cmax of 16.3 mg/L, AUC0-∞ of 97.2 mg·h·L-1, and cartilage concentration of 13.4 μg·g-1 at 800 mg/kg on day 1.
Produced a Cmax of 21.8 mg/L, AUC0-∞ of 143.1 mg·h·L-1, and cartilage concentration of 20.3 μg·g-1 at 1200 mg/kg on day 1.
Produced a Cmax of 9.4 mg/L and AUC0-∞ of 51.1 mg·h·L-1 at 400 mg/kg on day 6.
Produced a Cmax of 15.2 mg/L and AUC0-∞ of 95.4 mg·h·L-1 at 800 mg/kg on day 6.
Produced a Cmax of 23.7 mg/L and AUC0-∞ of 148.8 mg·h·L-1 at 1200 mg/kg on day 6.
Demonstrated similar Cmax and AUC0-∞ values on day 1 and day 6, indicating no drug accumulation with repeated dosing.
Molecular Weight

331.34

Formula

C17H18FN3O3
CAS No.
SMILES

O=C(C1=CN(C2CC2)C3=C(C=C(F)C(N4CCNCC4)=C3)C1=O)O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Ciprofloxacin Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Ciprofloxacin (GMP)85721-33-1Bay-09867 (GMP)BacterialTopoisomeraseAktβ-cateninPKBProtein kinase BBeta cateninhuman dental pulp stem cellsjuvenile rat chondrocyteshuman dermal papilla cellsmitochondrial topoisomerase IIEnterococcus faecalisbacterial DNA topoisomerase IIGSK3βbacterial topoisomerase IVInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Ciprofloxacin
Cat. No.:
HY-B0356G
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.